Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/β-catenin signaling pathway

被引:26
作者
Wei, Li-hui [1 ,2 ]
Lin, Jiu-mao [1 ,2 ]
Chu, Jian-feng [1 ,2 ]
Chen, Hong-wei [1 ,2 ]
Li, Qing-yu [1 ,2 ]
Peng, Jun [1 ,2 ]
机构
[1] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China
[2] Fujian Univ Tradit Chinese Med, Fujian Key Lab Integrat Med Geriatr, Fuzhou 350122, Fujian, Peoples R China
关键词
Scutellaria barbata D. Don; colorectal cancer; proliferation; Wnt/ beta-catenin pathway; TUMOR ANGIOGENESIS; COLON-CANCER; WNT; CELL; PROLIFERATION; APOPTOSIS; HEDGEHOG; IMPACT; P53;
D O I
10.1007/s11655-017-2775-3
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
To investigate the effect of the ethanol extract of Scutellaria barbata D. Don (EESB) on colorectal cancer (CRC) growth and Wnt/beta-catenin signaling pathway in vivo and in vitro. In vivo experiment, CRC xenograft mouse model was constructed with injection of HT-29 cells. Following xenograft implantation, twenty mice were randomly divided into EESB-treated group (n=10) and control group (n=10) by a random number table, and were given with intra-gastric administration of 2 g/kg EESB or saline, 5 days a week for 16 days, respectively. At the end of experiment, tumors were removed and weighed by electronic scales. The proliferation biomarker Ki-67 of tumor was evaluated by immunohistochemistry (IHC) assay. In vitro study, HT-29 cells were treated with 0, 0.5, 1.5, 2.5 mg/mL EESB for 24 h. At the end of the treatment, the viability and survival of HT-29 cells were determined by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay and colony formation assay, respectively. The mRNA expression of c-Myc, Survivin and adenomatous polyposis coli (APC) was examined by reverse transcription-polymerase chain reaction (RT-PCR) both in tumor tissues of CRC xenograft mice and HT-29 cells. Protein expression of c-Myc, Survivin, APC, and beta-catenin as well as beta-catenin phosphorylation level were evaluated by IHC assay or Western blotting. EESB significantly reduced tumor weight in CRC xenografts mice, compared with the control group (P < 0.05). IHC assay showed that EESB significantly inhibited protein expression of Ki-67 in tumor tissues (P < 0.05). MTT assay showed that EESB significantly reduced HT-29 cell viability in a dose-dependent manner (P < 0.05). Colony formation assay showed that EESB dose-dependently decreased the survival of HT-29 cells (P < 0.05). In addition, RT-PCR assay showed that EESB decreased the mRNA expression of c-Myc and Survivin and increased APC expression, both in tumor tissues of CRC xenograft mice and HT-29 cells (P < 0.05). IHC assay or Western blotting showed that EESB decreased protein expression of beta-catenin, c-Myc and Survivin, as well as increased APC expression and beta-catenin phosphorylation in tumor tissues or HT-29 cells (P < 0.05). EESB significantly reduced tumor growth in CRC xenografts mice, and inhibited the viability and survival of HT-29 cells. EESB could suppress the activation of the Wnt/beta-catenin pathway, which might be one of the mechanisms whereby Scutellaria barbata D. Don exerts its anticancer activity.
引用
收藏
页码:858 / 863
页数:6
相关论文
共 50 条
  • [41] Sevoflurane inhibits cholangiocarcinoma via Wnt/β- catenin signaling pathway
    Cheng, Hui
    Li, Qinfang
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [42] NEK2 promotes cancer cell progression and 5-fluorouracil resistance via the Wnt/β-catenin signaling pathway in colorectal cancer
    Cui, Facai
    Chen, Yu
    Wu, Xiaoyu
    Zhao, Weifeng
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [43] Therapeutic effects of -elemene via attenuation of the Wnt/β-catenin signaling pathway in cervical cancer cells
    Wang, Lufang
    Zhao, Yanyan
    Wu, Qiong
    Guan, Yifu
    Wu, Xin
    MOLECULAR MEDICINE REPORTS, 2018, 17 (03) : 4299 - 4306
  • [44] Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer
    Cheng, Xiaofei
    Xu, Xiangming
    Chen, Dong
    Zhao, Feng
    Wang, Weilin
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 110 : 473 - 481
  • [45] Lactobacillus species inhibitory effect on colorectal cancer progression through modulating the Wnt/β-catenin signaling pathway
    Ghanavati, Roya
    Akbari, Abolfazl
    Mohammadi, Fahime
    Asadollahi, Parisa
    Javadi, Abdolreza
    Talebi, Malihe
    Rohani, Mahdi
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2020, 470 (1-2) : 1 - 13
  • [46] LINC00365 promotes colorectal cancer cell progression through the Wnt/β-catenin signaling pathway
    Zhu, Yiping
    Bian, Yinzhu
    Zhang, Qun
    Hu, Jing
    Li, Li
    Yang, Mi
    Qian, Hanqing
    Yu, Lixia
    Liu, Baorui
    Qian, Xiaoping
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2020, 121 (02) : 1260 - 1272
  • [47] ENO3 Inhibits Growth and Metastasis of Hepatocellular Carcinoma via Wnt/β-Catenin Signaling Pathway
    Cui, Honglei
    Guo, Danfeng
    Zhang, Xiaodan
    Zhu, Yaohua
    Wang, Zhihui
    Jin, Yang
    Guo, Wenzhi
    Zhang, Shuijun
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [48] Ursolic Acid Suppresses Colorectal Cancer by Down-Regulation of Wnt/β-Catenin Signaling Pathway Activity
    Zhao, Hui
    Tang, Shun
    Tao, Qiu
    Ming, Tianqi
    Lei, Jiarong
    Liang, Yuanjing
    Peng, Yuhui
    Wang, Minmin
    Liu, Maolun
    Yang, Han
    Ren, Shan
    Xu, Haibo
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2023, 71 (09) : 3981 - 3993
  • [49] Biliverdin Reductase A (BLVRA) Promotes Colorectal Cancer Cell Progression by Activating the Wnt/β-Catenin Signaling Pathway
    Mao, Haiyan
    Xu, Yuan
    Zhang, Zhengrong
    Sun, Guozhuang
    Wang, Zhu
    Qiao, Dawei
    Yin, Xudong
    Liu, Siping
    Bo, Ping
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 2697 - 2709
  • [50] Evacetrapib Elicits Antitumor Effects on Colorectal Cancer by Inhibiting the Wnt/β-Catenin Signaling Pathway and Activating the JNK Signaling Pathway
    Hu, Limei
    Dong, Haiyan
    He, Lingyuan
    Shi, Mengchen
    Xiang, Nanlin
    Su, Yixi
    Wang, Chen
    Tian, Yu
    Hu, Yijia
    Wang, Huihui
    Liu, Huanliang
    Wen, Chuangyu
    Yang, Xiangling
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (09) : 1238 - 1245